The rheumatoid arthritis drugs market would grow at a CAGR of 1.72% over the predicted time frame. The market is expected to increase in value from US$ 61.05 Bn in 2022 to US$ 70 Bn in 2030.
The on rheumatoid
arthritis drugs Market, which provides a business strategy, research &
development activities, concise outline of the market valuation, valuable
insights pertaining to market share, size, supply chain analysis, competitive
landscape and regional proliferation of this industry.
Download
Free Sample@ https://www.precedenceresearch.com/sample/1755
Report Scope of the Rheumatoid Arthritis Drugs Market
| Report Coverage | Details |
| Market Size by 2030 | USD 70 Billion |
| Growth Rate from 2022 to 2030 | CAGR of 1.72% |
| Largest Market | North America |
| Fastest Growing Market | Asia-Pacific |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Molecule, Sales Channel, Route of Administration, Geography |
A recent
report provides crucial insights along with application based and forecast
information in the Global Rheumatoid arthritis drugs Market. The report
provides a comprehensive analysis of key factors that are expected to drive the
growth of this market. This study also provides a detailed overview of the
opportunities along with the current trends observed in the Rheumatoid
arthritis drugs market.
A
quantitative analysis of the industry is compiled for a period of 10 years in
order to assist players to grow in the market. Insights on specific revenue
figures generated are also given in the report, along with projected revenue at
the end of the forecast period.
Companies
and Manufacturers Covered
The study
covers key players operating in the market along with prime schemes and
strategies implemented by each player to hold high positions in the industry.
Such a tough vendor landscape provides a competitive outlook of the industry,
consequently existing as a key insight. These insights were thoroughly analysed
and prime business strategies and products that offer high revenue generation
capacities were identified. Key players of the global Rheumatoid arthritis
drugs market are included as given below:
Rheumatoid arthritis drugs Market Key Players
- AbbVie
- Boehringer Ingelheim GmbH
- Novartis AG
- Regeneron Pharmaceuticals, Inc.
- Pfizer, Inc.
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd.
- UCB S.A.
- Johnson & Johnson Services, Inc.
- Amgen, Inc.
Market Segments
- Pharmaceuticals
- NSAIDs
- Analgesics
- DMARDs
- Glucocorticoids
- Biopharmaceuticals
- Biologics
- TNF-α antagonists
- T-cell inhibitors
- CD20 antigen
- JAK inhibitors
- anti-IL6 biologics
- Biosimilars
- CD20 antigen
- TNF-α antagonists
By Sales Channel
- Prescription
- Over-the-Counter (OTC)
By Route of Administration
- Oral
- Parenteral
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Malaysia
- Philippines
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of the Middle East & Africa
Report Objectives
- To define, describe, and forecast the global rheumatoid
arthritis drugs market based on product, and region
- To provide detailed information regarding the major
factors influencing the growth of the market (drivers, opportunities, and
industry-specific challenges)
- To strategically analyze micromarkets1 with respect to
individual growth trends, future prospects, and contributions to the total
market
- To analyze opportunities in the market for stakeholders
and provide details of the competitive landscape for market leaders
- To forecast the size of market segments with respect to
four main regions—North America,
Europe, Asia Pacific and the Rest of the World (RoW)2
- To strategically profile key players and comprehensively
analyze their product portfolios, market shares, and core competencies3
- To track and analyze competitive developments such as
acquisitions, expansions, new product launches, and partnerships in the rheumatoid
arthritis drugs market
Table of Content
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Rheumatoid Arthritis Drugs Market
5.1. COVID-19 Landscape: Rheumatoid Arthritis Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Rheumatoid Arthritis Drugs Market, By Molecule
8.1. Rheumatoid Arthritis Drugs Market, by Molecule, 2022-2030
8.1.1 Pharmaceuticals
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Biopharmaceuticals
8.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Rheumatoid Arthritis Drugs Market, By Sales Channel
9.1. Rheumatoid Arthritis Drugs Market, by Sales Channel, 2022-2030
9.1.1. Prescription
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Over-the-Counter (OTC)
9.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Rheumatoid Arthritis Drugs Market, By Route of Administration
10.1. Rheumatoid Arthritis Drugs Market, by Route of Administration, 2022-2030
10.1.1. Oral
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Parenteral
10.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Rheumatoid Arthritis Drugs Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Molecule (2017-2030)
11.1.2. Market Revenue and Forecast, by Sales Channel (2017-2030)
11.1.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Molecule (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Sales Channel (2017-2030)
11.1.4.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Molecule (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Sales Channel (2017-2030)
11.1.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Molecule (2017-2030)
11.2.2. Market Revenue and Forecast, by Sales Channel (2017-2030)
11.2.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Molecule (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Sales Channel (2017-2030)
11.2.4.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Molecule (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Sales Channel (2017-2030)
11.2.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Molecule (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Sales Channel (2017-2030)
11.2.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Molecule (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Sales Channel (2017-2030)
11.2.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Molecule (2017-2030)
11.3.2. Market Revenue and Forecast, by Sales Channel (2017-2030)
11.3.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Molecule (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Sales Channel (2017-2030)
11.3.4.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Molecule (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Sales Channel (2017-2030)
11.3.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Molecule (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Sales Channel (2017-2030)
11.3.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Molecule (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Sales Channel (2017-2030)
11.3.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Molecule (2017-2030)
11.4.2. Market Revenue and Forecast, by Sales Channel (2017-2030)
11.4.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Molecule (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Sales Channel (2017-2030)
11.4.4.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Molecule (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Sales Channel (2017-2030)
11.4.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Molecule (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Sales Channel (2017-2030)
11.4.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Molecule (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Sales Channel (2017-2030)
11.4.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Molecule (2017-2030)
11.5.2. Market Revenue and Forecast, by Sales Channel (2017-2030)
11.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Molecule (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Sales Channel (2017-2030)
11.5.4.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Molecule (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Sales Channel (2017-2030)
11.5.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
Chapter 12. Company Profiles
12.1. AbbVie
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Boehringer Ingelheim GmbH
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Novartis AG
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Regeneron Pharmaceuticals, Inc
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Pfizer, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Bristol-Myers Squibb Company
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. F. Hoffmann-La Roche Ltd.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. UCB S.A.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Johnson & Johnson Services, Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Amgen, Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
0 Comments